Compass Pathways Restructures, Cuts Staff Amid Psilocybin Trial Delays
Key Insights
Compass Pathways is cutting 30% of its staff and halting early-stage research to focus on late-stage trials of its lead drug COMP360.
The company anticipates top-line data from its main Phase 3 trial in Q2 2025, with results from a second late-stage study pushed to H2 2026.
Increased regulatory scrutiny around maintaining the blinded nature of psychedelic drug trials has contributed to the delay.
Compass Pathways (NASDAQ: CMPS) is implementing a significant restructuring, including a 30% reduction in its workforce and the cessation of early-stage research programs, as it concentrates its resources on advancing late-stage trials of its primary asset, COMP360. This strategic shift follows the company's third-quarter financial results, which revealed a widening net loss of $38.5 million compared to $33.4 million in the previous year.
The London-based company's CEO, Kabir Nath, emphasized the critical importance of the COMP360 program, stating, "Ensuring the success of our lead COMP360 program is our absolute priority." The adjustment in the Phase 3 pivotal program timeline has necessitated a thorough review of operations to ensure that all resources are optimally aligned with this primary objective.
Trial Delays and Regulatory Scrutiny
Compass Pathways now projects that top-line data from its pivotal Phase 3 trial will be available in the second quarter of 2025. Results from a second late-stage study, COMP006, have been postponed to the second half of 2026. The company attributed these delays to "increased regulatory scrutiny" concerning the maintenance of blinding in psychedelic drug trials, requiring the release of data only after the 26-week follow-up period.
Financial Position and Market Response
Despite these challenges, Compass Pathways reported cash and cash equivalents of $207 million as of September 30, which the company believes will be sufficient to fund operations into 2026. However, the market reacted negatively to the announcement, with Compass shares plummeting more than 30% in early trading.
Strategic Shift and Competition
The restructuring occurs after RBC Capital Markets initiated coverage with an "Outperform" rating, projecting potential peak revenues of $2.3 billion from the psilocybin program. RBC analyst Leonid Timashev had set a $23 price target in July, citing a "high likelihood of a positive Phase 3 readout."
Compass Pathways faces competition from companies such as Cybin Inc. (search) (NYSE: CYBN) and the Usona Institute, a nonprofit organization conducting its own Phase 3 psilocybin trial for major depression (search). While Compass is exploring potential applications for post-traumatic stress disorder (search) and anorexia nervosa (search), the restructuring will halt preclinical efforts outside of the COMP360 program. R&D costs increased to $32.9 million in the third quarter, up from $21.5 million the previous year, driven by rising clinical trial expenses.